2-[2-(2-Naphthalen-1-yloxyethylsulfanyl)benzimidazol-1-yl]acetic acid | 312929-77-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-[2-(2-Naphthalen-1-yloxyethylsulfanyl)benzimidazol-1-yl]acetic acid
• CAS: 312929-77-4
• 化学式: C₂₁H₁₈N₂O₃S
• 分子量: 378.4
• InChiKey: ZYDROGODYYULOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  89.6
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS<br/>[FR] DERIVES DE L'ACIDE 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIQUE EN TANT QU'ANTAGONISTES DE CRTH2
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2006021418A1

  公开（公告）日：2006-03-02

  The invention relates to 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives and their use as potent 'chemoattractant receptor-homologous molecule expressed on Th2 cells' antagonists in the treatment of prostaglandin mediated diseases, to pharmaceutical compositions containing these derivatives and to processes for their preparation.

  这项发明涉及2-硫代基苯并咪唑-1-基乙酸衍生物及其在治疗前列腺素介导的疾病中作为强效“趋化受体同源分子在Th2细胞上表达”的拮抗剂的用途，涉及含有这些衍生物的药物组合物以及其制备方法。
• 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists
  申请人：Fretz Heinz

  公开号：US20080108638A1

  公开（公告）日：2008-05-08

  The invention relates to 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives and their use as potent “chemoattractant receptor-homologous molecule expressed on Th2 cells” antagonists in the treatment of prostaglandin mediated diseases, to pharmaceutical compositions containing these derivatives and to processes for their preparation.

  本发明涉及2-硫基苯并咪唑-1-基乙酸衍生物及其在治疗前列腺素介导的疾病中作为有效的“趋化因子受体同源分子表达在Th2细胞”拮抗剂的使用，以及含有这些衍生物的制药组合物和其制备过程。
• Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
  申请人：Texas Tech University System

  公开号：US10463649B2

  公开（公告）日：2019-11-05

  The present invention includes compositions and methods for inhibiting MCL-1, including novel inhibitors of MCL-1, and compositions and methods for treating a subject with cancer that is refractory to one or more MAPK pathway protein inhibitors.

  本发明包括抑制MCL-1的组合物和方法，包括MCL-1的新型抑制剂，以及治疗对一种或多种MAPK通路蛋白抑制剂难治的癌症患者的组合物和方法。
• 2-SULFANYL-BENZIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1784182A1

  公开（公告）日：2007-05-16
• Inhibitors of Mcl-1 as Drugs to Overcome Resistance to BRAF Inhibitors and MEK Inhibitors
  申请人：Texas Tech University System

  公开号：US20180161313A1

  公开（公告）日：2018-06-14

  The present invention includes compositions and methods for inhibiting MCL-1, including novel inhibitors of MCL-1, and compositions and methods for treating a subject with cancer that is refractory to one or more MAPK pathway protein inhibitors.